NewsBenzingaSignalé plus tôt, Jewett-Cameron Trading T4 BPA (0,10 $) en hausse par rapport à (0,64 $) sur un an, ventes à 7,675 M$ en baisse par rapport à 10,371 M$ sur un an Signalé plus tôt, Jewett-Cameron Trading T4 BPA (0,10 $) en hausse par rapport à (0,64 $) sur un an, ventes à 7,675 M$ en baisse par rapport à 10,371 M$ sur un an Benzinga 2026.11.20 05:41 (GMT+0) Open on Benzinga Other news Geospace Technologies (GEOS) Shares Tumble 16.47% After Hours: Here's Why Stock Market: Will S&P 500 Open Up or Down Today? Update: Geospace Technologies Q4 Adj. EPS $(0.86) Down From $(0.71) YoY, Sales $19.589M Down From $30.714M YoY ‘War of Necessity’: Trump Gets Senate Backing to Continue Fighting as Democrats Fail to Block Further Military Strikes Reported Earlier, Jewett-Cameron Trading Q4 EPS $(0.10) Up From $(0.64) YoY, Sales $7.675M Down From $10.371M YoY Reported Earlier, Revolution Medicines’ RASONQUE Plus Chemotherapy Shows 60.7% Confirmed ORR, 8.2% Complete Responses In 61 First-Line Metastatic Pancreatic Cancer Patients At 18.3-Month Median Follow-Up; Supports Phase 3 RASolute 303
Update: Geospace Technologies Q4 Adj. EPS $(0.86) Down From $(0.71) YoY, Sales $19.589M Down From $30.714M YoY
‘War of Necessity’: Trump Gets Senate Backing to Continue Fighting as Democrats Fail to Block Further Military Strikes
Reported Earlier, Jewett-Cameron Trading Q4 EPS $(0.10) Up From $(0.64) YoY, Sales $7.675M Down From $10.371M YoY
Reported Earlier, Revolution Medicines’ RASONQUE Plus Chemotherapy Shows 60.7% Confirmed ORR, 8.2% Complete Responses In 61 First-Line Metastatic Pancreatic Cancer Patients At 18.3-Month Median Follow-Up; Supports Phase 3 RASolute 303